<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>What are the current strategies to incentive antibiotic development? | 97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</title>
  <meta name="description" content="What are the current strategies to incentive antibiotic development? | 97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  <meta name="generator" content="bookdown 0.24.4 and GitBook 2.6.7" />

  <meta property="og:title" content="What are the current strategies to incentive antibiotic development? | 97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="What are the current strategies to incentive antibiotic development? | 97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  
  
  

<meta name="author" content="Russell E. Lewis, Associate Professor, Infectious Diseases, University of Bologna" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="why-has-antibiotic-discovery-faltered-in-recent-years.html"/>
<link rel="next" href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"/>
<script src="assets/header-attrs-2.11/header-attrs.js"></script>
<script src="assets/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="assets/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="assets/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="assets/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Welcome to the online course lecture notes</a></li>
<li class="chapter" data-level="" data-path="module-1-global-aspects-of-antimicrobial-resistance.html"><a href="module-1-global-aspects-of-antimicrobial-resistance.html"><i class="fa fa-check"></i>Module 1: Global Aspects of Antimicrobial Resistance</a>
<ul>
<li class="chapter" data-level="" data-path="a-brief-history-of-antimicrobial-resistance-amr.html"><a href="a-brief-history-of-antimicrobial-resistance-amr.html"><i class="fa fa-check"></i>A brief history of antimicrobial resistance (AMR)</a></li>
<li class="chapter" data-level="" data-path="global-response-to-antimicrobial-resistance-amr.html"><a href="global-response-to-antimicrobial-resistance-amr.html"><i class="fa fa-check"></i>Global response to antimicrobial resistance (AMR)</a></li>
<li class="chapter" data-level="" data-path="what-are-the-drivers-of-antimicrobial-resistance.html"><a href="what-are-the-drivers-of-antimicrobial-resistance.html"><i class="fa fa-check"></i>What are the drivers of antimicrobial resistance?</a></li>
<li class="chapter" data-level="" data-path="amr-in-low-middle-income-countries-lmics.html"><a href="amr-in-low-middle-income-countries-lmics.html"><i class="fa fa-check"></i>AMR in Low-Middle Income Countries (LMICs)</a>
<ul>
<li class="chapter" data-level="" data-path="amr-in-low-middle-income-countries-lmics.html"><a href="amr-in-low-middle-income-countries-lmics.html#how-can-the-effectiveness-of-antimicrobials-be-preserved"><i class="fa fa-check"></i>How can the effectiveness of antimicrobials be preserved?</a></li>
<li class="chapter" data-level="" data-path="amr-in-low-middle-income-countries-lmics.html"><a href="amr-in-low-middle-income-countries-lmics.html#case-study-a-successful-national-antibiotic-stewardship-program-in-a-lmic"><i class="fa fa-check"></i>Case study: A successful national antibiotic stewardship program in a LMIC</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="amr-situation-in-italy.html"><a href="amr-situation-in-italy.html"><i class="fa fa-check"></i>AMR situation in Italy</a></li>
<li class="chapter" data-level="" data-path="the-global-future-of-amr.html"><a href="the-global-future-of-amr.html"><i class="fa fa-check"></i>The global future of AMR</a></li>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html"><i class="fa fa-check"></i>One-Health Perspective of AMR</a>
<ul>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#antibiotic-use-in-animal-food-production"><i class="fa fa-check"></i>Antibiotic use in animal food production</a></li>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#the-impact-of-animal-antibiotic-use-on-human-amr"><i class="fa fa-check"></i>The impact of animal antibiotic use on human AMR</a></li>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#antimicrobial-resistance-in-animals-in-lmics"><i class="fa fa-check"></i>Antimicrobial resistance in animals in LMICs</a></li>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#environmental-concerns"><i class="fa fa-check"></i>Environmental concerns</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cross-border-spread-of-amr.html"><a href="cross-border-spread-of-amr.html"><i class="fa fa-check"></i>Cross-border spread of AMR</a></li>
<li class="chapter" data-level="" data-path="summary.html"><a href="summary.html"><i class="fa fa-check"></i>Summary</a></li>
<li class="chapter" data-level="" data-path="lecture-slides.html"><a href="lecture-slides.html"><i class="fa fa-check"></i>Lecture Slides</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="module-2-the-public-health-crisis-of-new-antibiotic-development.html"><a href="module-2-the-public-health-crisis-of-new-antibiotic-development.html"><i class="fa fa-check"></i>Module 2: The Public Health Crisis of New Antibiotic Development</a>
<ul>
<li class="chapter" data-level="" data-path="background.html"><a href="background.html"><i class="fa fa-check"></i>Background</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html"><i class="fa fa-check"></i>Why has antibiotic discovery faltered in recent years?</a>
<ul>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#scientific-challenges"><i class="fa fa-check"></i>Scientific challenges</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#antibiotic-regulatory-hurdles"><i class="fa fa-check"></i>Antibiotic regulatory hurdles</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><a href="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><i class="fa fa-check"></i>What are the current strategies to incentive antibiotic development?</a>
<ul>
<li class="chapter" data-level="" data-path="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><a href="what-are-the-current-strategies-to-incentive-antibiotic-development.html#antibiotic-supply-chain-problems"><i class="fa fa-check"></i>Antibiotic supply chain problems</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><a href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><i class="fa fa-check"></i>What can be done to ensure antibiotic access in LMICs?</a>
<ul>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><a href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html#barrier-1-weak-drug-discovery-difficulties-in-market-entry-and-poor-stewardship-lead-to-irrational-selection-and-use-of-antibiotics"><i class="fa fa-check"></i>Barrier 1: Weak drug discovery, difficulties in market entry, and poor stewardship lead to irrational selection and use of antibiotics</a></li>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><a href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html#barrier-2-antibiotics-are-not-affordable-for-many-in-lmics-and-government-funding-for-health-is-low"><i class="fa fa-check"></i>Barrier 2: Antibiotics are not affordable for many in LMICs and government funding for health is low</a></li>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><a href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html#barrier-3-weak-health-systems-unreliable-supply-chains-and-poor-quality-control-fail-to-deliver-antibiotics-to-patients-in-need"><i class="fa fa-check"></i>Barrier 3: Weak health systems, unreliable supply chains and poor quality control fail to deliver antibiotics to patients in need</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="summary-1.html"><a href="summary-1.html"><i class="fa fa-check"></i>Summary</a></li>
<li class="chapter" data-level="" data-path="lecture-slides-1.html"><a href="lecture-slides-1.html"><i class="fa fa-check"></i>Lecture Slides</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="module-3-antibiotic-and-diagnostic-test-availability-affordability-in-lmics.html"><a href="module-3-antibiotic-and-diagnostic-test-availability-affordability-in-lmics.html"><i class="fa fa-check"></i>Module 3: Antibiotic and diagnostic test availability, affordability in LMICs</a>
<ul>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><i class="fa fa-check"></i>COVID-19 Vaccine Access in Low-Middle Income Countries (LMICs)</a>
<ul>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#covid-19-vaccines-global-access-covax-program"><i class="fa fa-check"></i>COVID-19 Vaccines Global Access (COVAX) Program</a></li>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#is-the-covax-program-suceeding"><i class="fa fa-check"></i>Is the COVAX program suceeding?</a></li>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#access-to-sars-cov-2-testing-in-lmics"><i class="fa fa-check"></i>Access to SARS-CoV-2 testing in LMICs</a></li>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#infection-control-in-lmics"><i class="fa fa-check"></i>Infection control in LMICs</a></li>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#intensive-care-units-icus-in-lmics"><i class="fa fa-check"></i>Intensive care units (ICUs) in LMICs</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="access-to-covid-19-tools-accelerator-act.html"><a href="access-to-covid-19-tools-accelerator-act.html"><i class="fa fa-check"></i>ACCESS TO COVID-19 Tools Accelerator (ACT)</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html"><i class="fa fa-check"></i>Medicines Patent Pool</a>
<ul>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#mpp-and-covid-19"><i class="fa fa-check"></i>MPP and COVID-19</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#mpp-and-hiv"><i class="fa fa-check"></i>MPP and HIV</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#mpp-and-hepatitis-c"><i class="fa fa-check"></i>MPP and Hepatitis C</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#tuberculosis"><i class="fa fa-check"></i>Tuberculosis</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#is-the-medicines-patient-pool-working"><i class="fa fa-check"></i>Is the Medicines Patient Pool Working?</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="counterfeit-medications.html"><a href="counterfeit-medications.html"><i class="fa fa-check"></i>Counterfeit Medications</a>
<ul>
<li class="chapter" data-level="" data-path="counterfeit-medications.html"><a href="counterfeit-medications.html#specific-problems-with-counterfeited-antibiotics"><i class="fa fa-check"></i>Specific problems with counterfeited antibiotics</a></li>
<li class="chapter" data-level="" data-path="counterfeit-medications.html"><a href="counterfeit-medications.html#how-can-drug-counterfeiting-be-reduced"><i class="fa fa-check"></i>How can drug counterfeiting be reduced?</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="summary-covid-19-and-lessons-for-the-amr-crises.html"><a href="summary-covid-19-and-lessons-for-the-amr-crises.html"><i class="fa fa-check"></i>Summary: COVID-19 and lessons for the AMR crises</a></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="what-are-the-current-strategies-to-incentive-antibiotic-development" class="section level2 unnumbered">
<h2>What are the current strategies to incentive antibiotic development?</h2>
<p><strong>Incentives for antibiotics are categorized as either ‘push’ or ‘pull’. Push incentives occur before regulatory approval by the FDA or EMA, and the funding supports many projects, including the many that fail before approval. Pull incentives are paid only after regulatory approval and hence only successful products are supported. Both push and pull incentives are required to address the lack of antibiotic development.</strong></p>
<p>Many successful initiatives to establish push funding for antibiotics have been developed over the last decade. At present, major AMR development initiatives include:</p>
<ul>
<li><p><a href="https://www.phe.gov/about/barda/Pages/default.aspx">US Biomedical Advanced Research and Development Authority, BARDA</a> (1.2 billion dollars to support Phase 2/3 antibiotic development against 21st century threats including drug-resistant bacteria, supports CARB-X)</p></li>
<li><p><a href="https://carb-x.org/">CARB-X</a> (550 million, Hits to lead Phase 1 product development of therapeutics, diagnostics and preventatives against WHO and CDC priority drug-resistant bacteria)</p></li>
<li><p><a href="https://www.gardp.org/">The Global Antibiotic Research and Development Partnership, GARDP</a> (Produce discovery from discovery to delivery including novel therapeutics, optimizing antibiotics, developing combinations. Focused on WHO priority list).</p></li>
<li><p><a href="https://www.imi.europa.eu/projects-results/project-factsheets/enable">The European Gram Negative AntiBacterial Engine, ENABLE</a></p></li>
<li><p><a href="https://www.repair-impact-fund.com/">Novo Holdings REPAIR Impact Fund</a> (165 million investment in lead optimization to Phase I development of therapeutics and diagnostics against WHO priority drug-resistant bacteria.)</p></li>
<li><p><a href="https://www.jpiamr.eu">Joint Programming Initiative on Antimicrobial Resistance, JPIAMR</a> (novel therapeutics, diagnostics, surveillance, prevention, stewardship, WHO priority pathogens</p></li>
<li><p><a href="https://wellcome.org/">Wellcome Trust</a> (175 million drug-resistant infections focused on policy, strengthening evidence for action, clinical trial capabilities and innovative product development including CARB-X</p></li>
<li><p><a href="https://www.imi.europa.eu/">Innovative Medicines Initiative</a></p></li>
<li><p><a href="https://www.amractionfund.com/">AMR Action Fund</a> Joint program through WHO, European Investment Bank, and Wellcome Trust</p></li>
<li><p><a href="https://www.gov.uk/government/groups/the-global-amr-innovation-fund">UK AID</a> (315 million pounds funded through the Global AMR innovation fund and the Fleming Fund to help LMICs tackle AMR).</p></li>
<li><p>The <a href="https://www.gesundheitsforschung-bmbf.de/en/GlobalAMRHub.php">German Federal Ministry of Education and Research</a> support of national research programs as well as contributions to international initiatives like CARB-X, GARDP, and JPIAMR.</p></li>
<li><p><a href="https://www.gatesfoundation.org/">Bill &amp; Melinda Gates Foundation</a> (124 million targeting drug-resistant infections in low-middle income countries (LMICs), disease surveillance, vaccine development, economic modeling, and CARB-X</p></li>
<li><p><a href="https://www.niaid.nih.gov/research/antimicrobial-resistance">U.S. National Institutes of Health</a> (1.4 billion dollars funding basic research, academic industry startup partnerships, and other research and development against bacterial threats, for vaccines, therapeutics and diagnostics</p></li>
</ul>
<p>The arrival of these push incentives for antibiotics are creating some progress. The preclinical pipeline is shifting to higher quality products targeting the most urgent clinical needs, reducing the economic risk for antibiotic discovery. Without these programmes, the fragile pipeline would have likely become entirely moribund. Yet the bankruptcy of Achaogen in April 2019 and subsequent other companies working in the antibiotic sector provided a wake-up call for the antibiotics industry: <strong>the finish line is not FDA or EMA approval, but break-even profitability.</strong> For Achaogen, scientific and regulatory achievement ended in economic disaster. A similar fate awaits other antibiotic companies unless governments enact meaningful pull incentives in the next year.</p>
<figure>
<center>
<p><img src="images/push.png" /></p>
</center>
<figcaption>
<p><strong>Figure 5. Push versus pull incentives for antibiotic development.</strong></p>
</figcaption>
</figure>
<p>Pull incentives are increasing the focus of of new initiatives to develop antibiotics in the United States and Europe, building on the release of the <a href="http://drive-ab.eu/wp-content/uploads/2018/01/DRIVE-AB-Final-Report-Jan2018.pdf">DRIVE-AB final report in 2018.</a> Clearly, effective pull funding will require substantial public investment that may not be politically popular if viewed as a large cash “handout” to pharmaceutical companies. Some novel reimbursement schemes with pull incentives for antibiotic development are starting (recently reviewed by Gotham et al[<span class="citation"><sup>11</sup></span>). <strong>One of the most frequently discussed pull incentives is the “Netflix reimbursement model” that is currently being implemented pilot projects in the <a href="https://www.gov.uk/government/news/world-first-scheme-underway-to-tackle-amr-and-protect-uk-patients">UK</a> and <a href="https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/antibiotics-and-antimicrobial-resistance/availability-of-antibiotics/">Sweden</a>.</strong> This payment mechanism is based on a <strong>‘de-linkage’ reimbursement approach</strong> because it seperates the payments to innovators/ manufacturers from the number of antibiotic units sold.</p>
<figure>
<iframe src="https://www.ft.com/video/adada10f-5747-4976-a3e0-958b0165e0ef" loading="lazy" style="width: 100%; height: 600px; border: 0px none;">
</iframe>
<figcaption>
<p><strong>Figure 6. Financial Times Video Examining the “Netflix Model” of Pull Incentives for Antibiotic Reimbursement.</strong></p>
</figcaption>
</figure>
<p>How can the <strong>true value</strong> of antibiotics be better communicated to the public? Two leading experts in the economics of antibiotic resistance (Drs. John Rex and Ken Outterson) have suggested that antibiotics should be thought of more like the “fire-extinguishers” of medicine.</p>
<blockquote>
<p>“No one wakes up hoping they get to use a fire extinguisher that day. Not even the fire department. Fire fighters go to work every day and hope they don’t get any calls. They perform regular maintenance on all their gear and stay at the station 24/7 just as a precaution. We pay them to be available and prepared so they can come to our rescue when we need them. If we didn’t pay for the fire department for years and then a fire broke out in the middle of your town, can you imagine the damage? People would die unnecessarily, the medical system would be overwhelmed, and the fire could spread beyond the borders of the town. The fire might rage through the whole county, then the region, and then your entire country. It might even spread through the entire world, just like COVID-19. <br> <br> A fire fighter uses a hose to subdue flames engulfing a home while a physician uses antibiotics to stop an infection in your body. We need to be prepared for fires – the flame kind and the medical kind. As a society, we are prepared for the flame kind. But the medical? We aren’t even close. <br> Without antibiotics, all of modern medicine will change worldwide. Diseases we think of only being in the history books could become a part of every day life again. Minor surgery could become life threatening. An infected cut on your hand could be the end. Childbirth will easily endanger the lives of mothers and newborns. Cancer treatments will be nearly impossible. Antibiotics are vitally important to all of humanity”. <br> <br> -<a href="https://amr.solutions/fire-extinguishers-of-medicine/">John Rex, M.D., AMR Solutions</a></p>
</blockquote>
<figure>
<center>
<p><img src="images/fire%20extinguisher-01.png" /></p>
</center>
</figure>
<p><br>For more information on how AMR risks can be responsibly and effectively communicated to the public, see this excellent video prepared by the Wellcome Trust: [Drug-resistant infections: the power of language (<a href="https://www.youtube.com/watch?v=wTgRpOIxNG0&amp;t=6s">https://www.youtube.com/watch?v=wTgRpOIxNG0&amp;t=6s)ù</a>ù){.uri} <br></p>
<style>
div.blue { background-color:#e6f0ff; border-radius: 5px; padding: 20px;}
</style>
<div class="blue">
<p><strong>For further study:</strong> Tetraphase pharmaceuticals is a small company with a innovative and unique chemistry platform for developing novel tetracycline analogues that have activity against several organisms on the WHO Priority Pathogens List. Their lead compound, eravacycline, was appoved by the FDA for the treatment of complicated intraabdominal infections in 2018. Like many of its peers, merely securing approval was only the first hurdle. What has happened since to everacycline and Tetraphase pharmaceuticals? How could a different reimbursement scheme changed outcomes?</p>
</div>
<div id="antibiotic-supply-chain-problems" class="section level3 unnumbered">
<h3>Antibiotic supply chain problems</h3>
<p>Although much of the focus on antibiotic availability is focused on new drugs for AMR, another worrying phenomenon is the increasing shortages of older generics, mostly injectable antibacterials, such as piperacillin-tazobactam or benzylpenicillin. Drug shortages are another factor that can contribute to AMR, as drugs ideally reserved for critically-ill patients or MDR infections may need to be susbstituted when supply problems for first-line antibiotic arise.<span class="citation"><sup>12</sup></span> The fierce price competition combined with stringent production requirements for parenteral antibacterials has led to a significant reduction of suppliers, in particular of active pharmaceutical ingredients, and to highly optimized and thus more vulnerable supply chains. Increasingly prevalent shortages of even older antibiotics is now recognized as a major public health threat and requires additional specific action.</p>
<figure>
<center>
<p><br></p>
<p><img src="images/drugshortages.jpg" width="800" /></p>
</center>
<figcaption>
<center>
<p><strong>Figure 7</strong> The reasons for antimicrobial shortages across the development, distribution and use pathway.</p>
</center>
</figcaption>
</figure>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="why-has-antibiotic-discovery-faltered-in-recent-years.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="assets/gitbook-2.6.7/js/app.min.js"></script>
<script src="assets/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="assets/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
},
"toolbar": {
"position": "static"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
